AveXis, a Novartis company, announced today that the European Commission (EC) have granted conditional approval for Zolgensma for the treatment of patients with 5q SMA, activating a ‘Day One’ access programme.

For the week commencing 18th May 2020 TreatSMA want to see your creative baking skills. Entries will be judged on decoration and the look of the cake when cut. There is also a 3rd category for creativity if you are unable to get traditional ingredients.

For the week commencing 18th May 2020 TreatSMA want to see your creative baking skills. Entries will be judged on decoration and the look of the cake when cut. There is also a 3rd category for creativity if you are unable to get traditional ingredients.

We have pleasure in announcing the exciting news that Roche today submitted their application for an Early Access to Medicines Scheme (EAMS), a UK specific early access program which is approved by the MHRA.

We have pleasure in announcing the exciting news that Roche today submitted their application for an Early Access to Medicines Scheme (EAMS), a UK specific early access program which is approved by the MHRA.

Key findings: Significant finding that infants were sitting greater than 5 seconds after a year on treatment. A significant improvement in motor function children achieved unexpected milestones of sitting or even standing majority of children maintained ability to swallow

Key findings: Significant finding that infants were sitting greater than 5 seconds after a year on treatment. A significant improvement in motor function children achieved unexpected milestones of sitting or even standing majority of children maintained ability to swallow

TreatSMA are extremely happy and proud to announce that Marni Smyth has become the sixth trustee that has joined our team. Marni has been in discussions with TreatSMA for a number of weeks and we take great pleasure in announcing the news.